

MERGER ANNOUNCEMENT M/25/065 – CELLTRION/IMCLONE SYSTEMS

Section 21 of the Competition Act 2002

Competition and Consumer Protection Commission clears proposed acquisition by Celltrion, Inc. of sole control of ImClone Systems LLC

31 October 2025

The Competition and Consumer Protection Commission has today cleared the proposed transaction whereby Celltrion, Inc. through Celltrion USA, Inc. would acquire sole control of ImClone Systems LLC. The proposed transaction was notified under the Competition Act 2002, as amended, on 16 October.

The Commission has formed the view that the proposed transaction will not substantially lessen competition in any market for goods or services in the State. The Commission will publish the reasons for its determination on its website no later than 60 working days after the date of the determination and after allowing the parties the opportunity to request that confidential information be removed from the published version.

Additional Information

Celltrion, Inc. is a publicly traded South Korean biopharmaceutical company engaged in the development and global supply of biosimilars, biologics and small molecule drugs.

Celltrion USA, Inc. is a Delaware-incorporated subsidiary of Celltrion, Inc. Celltrion USA, Inc. is active in the distribution and regulatory management of Celltrion, Inc.'s pharmaceutical products in the United States. Celltrion USA, Inc. has a presence in the State through its subsidiary, Celltrion Healthcare Ireland Limited.

ImClone Systems LLC is incorporated as a limited liability company in Delaware, United States. ImClone Systems LLC is active in the pharmaceutical sector through its biopharmaceutical manufacturing facility in Branchburg, New Jersey which produces active pharmaceutical ingredients (APIs).